We are not the economic modelers. We're relying on information from the Parliamentary Budget Officer, who has modelled that information and has looked at what that would do to biosimilars and how that would act in the market, and what those costs would be to pharmacare. I urge people to look at the Parliamentary Budget Officer's report, which answers many of those questions.
On June 18th, 2019. See this statement in context.